CorMedix Says It Believes 2027 DefenCath Revenue Guidance Should Be Suspended
CorMedix said it believes suspending previously issued 2027 DefenCath revenue guidance is appropriate and will defer future guidance until early 2027.
Related stories
Nebius Falls 11.6% as Revenue Forecast Misses Estimates
Nebius shares are down 11.6% after the AI cloud company’s revenue forecast missed estimates.
M impact | EARNINGS | Nov 12, 2026, 01:38 PM UTC
Nebius CFO now expects 2026 revenue of $3B to $3.2B
Nebius's CFO now expects revenue of $3 billion to $3.2 billion in 2026.
M impact | EARNINGS | Nov 12, 2026, 01:21 PM UTC
Cellebrite Raises FY26 Adjusted EBITDA Forecast to $163M–$166M
Cellebrite raised its FY26 adjusted EBITDA forecast to $163 million–$166 million.
M impact | EARNINGS | Nov 12, 2026, 01:14 PM UTC
Nebius CEO Expects Pre-Tax Profitability in Q4 2027
M impact | EARNINGS | Nov 12, 2026, 01:13 PM UTC
SHARES IN BANCO DO BRASIL FALL MORE THAN 10% AFTER Q3 RESULTS, GUIDANCE CHANGES
L impact | EARNINGS | Nov 12, 2026, 01:11 PM UTC
Banco do Brasil CFO Sees Profitability Staying Below Pre-Default-Spike Levels
The CFO also sees Q4 and Q1 2027 as challenging.
M impact | EARNINGS | Nov 12, 2026, 01:10 PM UTC